key: cord-0971264-xlxcg8zc authors: Cao, Liming; Ren, Lijie title: Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report date: 2021-02-01 journal: Acta Neurol Belg DOI: 10.1007/s13760-021-01608-2 sha: 88a539197a648eacc348945b9084b211fac7f421 doc_id: 971264 cord_uid: xlxcg8zc nan antibodies to major pathogens and cultures of bacteria and fungi; high-throughput genome sequencing also revealed no pathogens. SARS-CoV-2 antibodies were negative in the CSF on day 1 and in her blood on day 2 after admission. SARS-CoV-2 immunoglobulin G was present in the blood on day 5 after admission. Oligoclonal bands in blood and CSF were negative, and CSF antibodies, including anti-aquaporin-4, anti-myelin basic protein, anti-myelin oligodendrocyte glycoprotein, anti-glial fibrillary acidic protein, autoimmune encephalitis, and paraneoplastic syndrome, were negative. Six nasal swab tests for SARS-CoV-2 nucleic acid amplification performed at different times during hospitalization were negative. HIV, autoimmune vasculitis, anticardiolipin, and anti-nuclear antibody tests of blood were all negative. Initial brain magnetic resonance imaging (MRI) showed abnormal signals in the bilateral temporal cortex ( Fig. 1a-h) . Repeat brain MRI on day 10 showed an increased number of lesions, which were more striking in appearance ( Fig. 1i-l) ; the lesions were improved by day 15 (Fig. 1m-p) . The patient was administered intravenous (IV) ceftriaxone 2 g/days for 12 days and acyclovir 1.5 g/days for 16 days. Her headache, low-grade fever, and muscle aches were relieved while undergoing during treatment, although her poor memory persisted. She had a generalized tonic-clonic seizure 1 week after admission. An electroencephalogram showed epileptiform waves. She was immediately administered IV diazepam 10 mg and oral levetiracetam 1 g/ days, with no seizure recurrence. She was administered IV immunoglobulin 20 g/days for 5 days starting on day 11, and her MMSE scores improved to 29/30 on day 15. On a visit 1 month after discharge, she felt no discomfort, and a repeat MRI showed complete resolution of brain lesions. Our patient met the diagnostic criteria set by the International Pediatric MS Study Group [4] , and alternative diagnoses, such as infectious or autoimmune encephalitis, were excluded in our patient. ADEM following vaccination is a well-known entity and is, hence, not surprising following SARS-CoV-2 vaccination. In this case, a protective antibody was produced after vaccination. MRI typically shows reversible, large (> 1-2 cm), bilateral, white matter lesions, and deep gray matter lesions of the brain. CSF analysis may reveal a mild pleocytosis and elevated protein levels, but it is generally negative for intrathecal oligoclonal immunoglobulin G synthesis [2] . Systemic corticosteroids are firstline therapy [5] , and patients have an excellent response to gamma-globulin [6] . A brief literature review did not identify a case similar to ours. ADEM has not been reported following SARS-CoV-2 Availability of data and material Not applicable. Conflicts of interest The authors declare that there is no conflict of interest. The study design was approved by the ethics review board of the 3rd Affiliated Hospital of Shenzhen University (No: 2021-LHYYKY-LW-001). Informed consent Informed consent was obtained from the patient included in the case report. The patient provided written, informed consent for the publication of this case. Post-vaccination encephalomyelitis: literature review and illustrative case Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome Vaccination-associated acute disseminated encephalomyelitis Consensus definitions proposed for pediatric multiple sclerosis and related disorders Acute disseminated encephalomyelitis Acute disseminated encephalomyelitis in the intensive care unit: clinical features and outcome of 20 adults